Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. Issue 7 (13th April 2018)

• Record Type: Journal Article
• Authors: Meijer, Berrie; Mulder, Chris J J; Bouma, Gerd; Ponsioen, Cyriel Y; van der Woude, C Janneke; van der Meulen, Andrea E; Wintjens, Dion S J; Dijkstra, Gerard; Hoentjen, Frank; Oldenburg, Bas; van Bodegraven, Adriaan A; de Boer, Nanne K H
• Is Part Of: Inflammatory bowel diseases. Volume 24:Issue 7(2018)
• Page Start: 1558
• Page End: 1565
• Publication Date: 2018-04-13
• Subjects: thiopurines -- rescue therapy -- methotrexate -- thioguanine -- inflammatory bowel disease -- ulcerative colitis; Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izy047
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract: Background: Patients with active ulcerative colitis (UC) failing conventional therapies are in need of rescue strategies. Due to the fact that accepted step-up therapy with biologicals is expensive and sometimes unavailable, alternative therapies are warranted. Methotrexate (MTX) and thioguanine (TG) have both been suggested as alternative maintenance strategies in conventional thiopurine failing UC patients. In this multicenter database study, we compared safety and effectiveness (drug-survival) of MTX and TG in UC patients. Methods: We collected data from the Parelsnoer database, a prospective Dutch national database consisting of inflammatory bowel disease patients from all university hospitals in The Netherlands. Additional data were collected from detailed chart review. Results: In total, 99 UC patients were included, of which 48 used TG, 43 used MTX, and 8 patients had a history of both TG and MTX use. In 12% of the patients, biological therapy had failed. Roughly 70% of the patients in both groups were able to continue therapy for over 1 year. Adverse events were noted in 33% of all the patients and were mainly elevated liver enzymes or gastrointestinal complaints. Twenty-eight patients (28%) continued therapy (15 TG, 13 MTX) without the need of escalation therapy (eg, corticosteroids, biologicals, or surgery). Drug survival curves of both drugs were comparable, just as the number of patients with sustained clinical benefit of therapy ( P > 0.05). Conclusion: Both MTX and TG may be used and maintained as rescue therapy with sustained clinical benefit in one-third of the UC patients failing conventional therapies.